Low Breast Cancer
📧 Sign up to get email alerts when something new happens for Low Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer [Phase 1]
This Phase 1 clinical trial evaluates the safety of combining CX-5461 (Pidnarulex) with Trastuzumab Deruxtecan (T-DXd) in patients with HER2…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype [Phase 2]
A Phase 2 trial comparing trastuzumab deruxtecan versus CDK4/6 inhibitor–based endocrine therapy as first-line treatment for HR-positive, HE…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors [Phase 1]
This is a Phase 1 study evaluating CGT6297, a mutant-selective inhibitor, in adults with advanced solid tumors, including PIK3CA-mutant endo…
-
CLINICAL_TRIALS trial_result · 2026-02-13Clinical Trial Update: ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer [Phase 2]
A Phase 2 trial evaluating ARX788 for HER2-low breast cancer (locally advanced unresectable or metastatic) is currently not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-30Clinical Trial Update: Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer [Phase 3]
A Phase 3 trial update reports on neoadjuvant Pyrotinib for hormone-receptor-positive, HER2-low high-risk early breast cancer, with the tria…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer
A clinical trial investigating the efficacy and safety of trastuzumab-rezetecan in HER2-expressing breast cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
Daiichi Sankyo is conducting a trial to evaluate the effectiveness of trastuzumab deruxtecan in Chinese patients with breast cancer, includi…
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC [Phase 2]
This clinical trial update covers a Phase 2 study evaluating sequencing of antibody-drug conjugates in estrogen receptor-positive, HER2-low/…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC
This trial evaluates HER2-PET imaging as a precision tool to guide treatment with a HER2-targeted antibody-drug conjugate in metastatic brea…
-
CLINICAL_TRIALS research · 2025-10-24Clinical Trial Update: TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd [Phase 2]
A Phase 2 trial (TRADE DXd) evaluating two antibody-drug conjugates, Dato-DXd and T-DXd, for ADC-refractory breast cancer including HER2-low…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: TRUDI: TDXD+Durva in HER2+/Low IBC [Phase 2]
Phase 2 trial TRUDI is evaluating trastuzumab deruxtecan (TDXd) plus durvalumab (Durva) in HER2-positive and HER2-low invasive and inflammat…
-
CLINICAL_TRIALS trial_result · 2025-08-07Clinical Trial Update: Efficacy and Safety of T-DXd in Patients With HER2-positive and HER2-low Metastatic Breast Cancer: a Real-world Study
This real-world study updates the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive and HER2-low metastat…
-
CLINICAL_TRIALS research · 2025-06-15Clinical Trial Update: A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients [Phase 2]
A Phase II clinical trial is evaluating HLX22 in combination with trastuzumab deruxtecan for HER2-low, hormone receptor-positive breast canc…
-
CLINICAL_TRIALS research · 2025-03-20Clinical Trial Update: Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer
Sun Yat-sen University is leading a study evaluating optimized sequential treatment strategies with antibody-drug conjugates in HER2-low exp…
-
CLINICAL_TRIALS trial_result · 2024-12-13Clinical Trial Update: A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating trastuzumab deruxtecan in combination with immunotherapy as neoadjuvant treatment for HR-positive, HER2-lo…
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer
Observational study of patients treated with trastuzumab deruxtecan (Enhertu) for HER2-positive and HER2-low unresectable/metastatic breast …
-
CLINICAL_TRIALS research · 2024-11-04Clinical Trial Update: A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer [Phase 2]
A Phase 2 clinical trial assessing SHR-A1811 as neoadjuvant therapy for HR-positive, HER2-low breast cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients [Phase 2]
Phase 2 neoadjuvant trial evaluating SHR-A1811 plus adebrelimab in untreated HR-negative/low and HER2-low breast cancer; the study is not ye…